Hankang Capital focuses on the in-depth research in major diseases and unmet clinical needs, promoting the establishment of startups with first-tier teams and technology platforms. Hankang also provides professional insights, experience, and resources in product pipelines, team formation, application for registration, and clinical trials, to promote the startups becoming an industry leader.
Since the establishment of the company，Hankang has invested in Eastern Biotech, Innocare, Abbisko Therapeutics, Teligene Ltd, Chipscreen, Akeso Biopharma, LP Pharma，Wuhan Hiteck(code: 300683),etc which are the leaders in the industry.
Hankang Capital was awarded‘Top 100 Venture Capital Institutions’and‘Top 20 Investment Institutions in the Healthcare Sector’issued by Zero2IPO Group
Company Details
- Employees
- 8
- Founded
- -
- Address
- Room 6002, No.555, Haiyangxi Road, Shanghai,china
- Industry
- Venture Capital And Private Equity Principals
- NAICS
-
Miscellaneous Intermediation
- Keywords
- pharmaceutical, Biotech, Medical Device.
- HQ
- Shanghai
Hankang Capital Questions
Hankang Capital's LinkedIn profile is https://cn.linkedin.com/company/hankang-capital
Hankang Capital has
8 employees.
View email and phone details for 8
employees at Hankang Capital.
Hankang Capital's industry is
Venture Capital and Private Equity Principals
Hankang Capital's top competitors are
Med-Fine Capital,
浩悦资本,
Jifeng Ventures 济峰资本,
Ince Capital,
Longbio Pharma,
3e Bioventures Capital,
Cbc Group,
Haleon,
Cd Capital,
云时资本 Seas Capital.
Hankang Capital's categories are Venture Capital and Private Equity Principals
Hankang Capital's founding year is 2010
